Altus Pharmaceuticals Inc.
Altus Pharmaceuticals Announces Achievement of Primary Endpoint in Phase 3 Efficacy Trial of Trizytek for Cystic Fibrosis Patients with Pancreatic Insufficiency
Published in Genetics and Environmental Business Week, August 28th, 2008
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that its Phase 3 efficacy trial of Trizytek(TM) (porcine-free enzymes) in patients with cystic fibrosis (CF) successfully met its primary endpoint of improvement in fat absorption. The Company released top-line results from its 163 patient, double-blind, placebo-controlled trial of Trizytek, an enzyme replacement therapy for patients with pancreatic insufficiency. Trizytek is a stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. Altus' Trizytek Phase 3 clinical program is the largest ever conducted to evaluate the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Abraxis BioScience
CNSI at UCLA to Host Forum on New Technologies for Brain, Spinal Trauma - Autism
Help with Autism, Down Syndrome & other Special Needs; the TV Teacher Releases Its Newest Program! - Autoimmune Disease
Despite Risks, Powerful Drugs Offer Hope and Relief to Autoimmune Patients - Bone Research
Study data from Amgen, Inc. update understanding of bone research - Breast Cancer
Young Women May Be Underrepresented In Breast Cancer Research Studies & Treatment Says Genomics Expert - Cytomegalovirus
New findings from Kenton Laboratories in the area of cytomegalovirus described - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
